The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...

(Competitive Insight/Unsplash) While GLP-1 drugs such as Wegovy and Ozempic are now being broadly championed and widely used, ...

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

A peer-reviewed analysis of U.S. adverse event data has found that patients taking Wegovy face nearly five times the risk of a sudden, sight-threatening eye condition compared with those on Ozempic, ...

Novo Nordisk NVO announced that the FDA has approved Wegovy HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess ...

FDA approves higher 7.2mg Wegovy dose for Novo Nordisk (NVO), showing 20.7% weight loss. April launch aims to challenge Eli ...

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

Researchers found that the odds of developing an eye condition that leads to vision loss were about 5 times higher among those on Wegovy than among those on Ozempic.

Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author ...

Wegovy may raise the risk of "eye stroke" and vision loss, especially in men, compared to Ozempic due to higher doses of the ...

Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their mechanisms ...

From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper ...